These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors. Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496 [TBL] [Abstract][Full Text] [Related]
29. [The management of Hodgkin's disease with chemotherapy or combined modality treatment]. Tsushita K; Utsumi M; Shimoyama M Gan To Kagaku Ryoho; 1998 Dec; 25(14):2202-9. PubMed ID: 9881076 [TBL] [Abstract][Full Text] [Related]
30. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578 [TBL] [Abstract][Full Text] [Related]
31. MOPP, ABVD, or both to treat Hodgkin's disease. Martino R; Nomdedeu J; Brunet S N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680766 [No Abstract] [Full Text] [Related]
32. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805 [TBL] [Abstract][Full Text] [Related]
33. Comparison of MOPP/MOPP +/- RT vs. MOPp/ABVD +/- RT in poor prognosis Hodgkin's disease. Long-term results. Comella P; Abate G; Fiore M; Di Finizio G; Frezza P; Scoppa G; Anania C; Coucourde F; Zarrilli D J Chemother; 1989 Jul; 1(4 Suppl):1254-6. PubMed ID: 16312855 [No Abstract] [Full Text] [Related]
34. [Use of combined cystostatic therapy in the late stage of Hodgkin's disease]. Berényi E Orv Hetil; 1976 May; 117(22):1337-40. PubMed ID: 934630 [No Abstract] [Full Text] [Related]
37. Updated Hodgkins' disease. C. Advanced disease and special problems. Advances in chemotherapy. Frei E; Luce JK JAMA; 1973 Jan; 223(2):166-8. PubMed ID: 4739456 [No Abstract] [Full Text] [Related]
38. Combined chemotherapy cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) vs. CVPP plus CCNU (CCVPP) in Hodgin's disease. Morgenfeld M; Somoza N; Magnasco J; Pavlovsky S; de Bonesana AC; Bezares R; Suárez A; Pileggi J; Lein JM; Macchi A; Calabria SI; Garay GE; de Sica SC; Besuschio S Cancer; 1979 May; 43(5):1579-86. PubMed ID: 376095 [No Abstract] [Full Text] [Related]
39. [Successful chemotherapy of cancer. Remission of Hodgkin's disease. IV]. Lopez M Clin Ter; 2001; 152(3):203-6. PubMed ID: 11692542 [No Abstract] [Full Text] [Related]